Applications of Transcranial Magnetic Stimulation to Therapy in Psychiatry

Psychiatric TimesPsychiatric Times Vol 21 No 9
Volume 21
Issue 9

Transcranial magnetic stimulation has been applied in a growing number of psychiatric disorders as a putative treatment. As a focal intervention that may exert lasting effects, TMS offers the hope of targeting underlying circuitry and ameliorating the effects of psychiatric disorders. The ultimate success of such an approach depends upon our knowledge of the neural circuitry involved, on how TMS exerts its effects and on how to control its application to achieve the desired effects. Current challenges in the field include determining how to enhance the efficacy of TMS in these disorders and how to identify patients for whom TMS may be efficacious.

Transcranial magnetic stimulation (TMS) is a non-invasive means of stimulating focal regions of the brain using magnetic fields. Since its introduction in 1985, TMS has been used to study localization of brain functions, connectivity of brain regions and pathophysiology of neuropsychiatric disorders. The potential uses of TMS to treat psychiatric disorders are under active study. This article reviews the state of knowledge about the therapeutic potential of TMS in psychiatry.

The TMS Process

Transcranial magnetic stimulation is an investigational medical procedure performed by placing an electromagnetic coil on the scalp (Figure). High-intensity current is rapidly turned on and off in the coil through the discharge of a capacitor. This produces a time-varying magnetic field that lasts for about 100 to 200 microseconds. The magnetic field strength is about 1.5 to 2 tesla (about the same intensity as the static magnetic field used in clinical magnetic resonance imaging) at the surface of the coil, but the strength of the magnetic field drops off exponentially with distance from the coil. The proximity of the brain to the time-varying magnetic field results in current flow in neural tissue and in membrane depolarization. Transcranial magnetic stimulation is experimental; it is not approved by the U.S. Food and Drug Administration for the treatment of any disorder.

A striking effect of TMS occurs when one places the coil on the scalp over the primary motor cortex. A single TMS pulse of sufficient intensity causes involuntary movement in the muscle represented by that region of cortex. Thus, a TMS pulse produces a powerful but brief magnetic field that passes through the skin, soft tissue and skull. This induces electrical current in neurons, causing depolarization that then has behavioral effects. The minimum magnetic field intensity needed to produce motor movement is known as the individual motor threshold.

Repeated application of TMS pulses at regular intervals is called repetitive TMS (rTMS). The physiological effects of TMS depend upon the site and frequency of stimulation. If the stimulation occurs faster than once per second (1 Hz), it is referred to as fast rTMS and can result in excitatory physiologic changes. On the contrary, if the frequency is low, it is referred to as slow rTMS and can have an inhibitory effect on brain excitability. High-frequency rTMS carries a risk of seizure. Guidelines exist to reduce this risk by appropriate screening of participants for seizure risk factors, titrating the individual motor threshold and limiting rTMS dosage (Belmaker et al., 2003; Wassermann, 1998).

The ability to focally alter cortical excitability opens up the potential to modulate cortical circuitry for potential therapeutic benefit. The focality of the effects also presents a challenge to clinical application, because it is necessary to know the circuitry of the underlying disorder to guide where and how to stimulate to ameliorate its symptoms.

Major Depression

Major depression has been the focus of the bulk of TMS clinical trials to date. Initial work used nonfocal coils positioned over the vertex and found some suggestions of clinical benefit. Based on evidence for prefrontal abnormalities in depression, it was thought that rTMS over the prefrontal cortex could produce a more profound antidepressant effect than over other cortical areas. To test this hypothesis, using a within-participant crossover design, Pascual-Leone and colleagues (1996) reported that fast left dorsolateral prefrontal cortex (DLPFC) rTMS for five days had marked antidepressant effects, even for psychotic depression. Stimulation at other sites (right DLPFC, vertex) and sham treatment had no effect. This remarkable result was superior to what could be expected with any medication regimen or even electroconvulsive therapy, but most of the following studies could not replicate the same magnitude or speed of response using similar parameters and length of stimulation.

Extending the treatment to two weeks and increasing the number of pulses per day, a 50% response rate was reported in patients with medication-resistant unipolar depression in an open trial (Triggs et al., 1999). A double-blind, sham-controlled, single-crossover study of fast left DLPFC rTMS in medication-resistant outpatients found improvements with two weeks of active rTMS, but the degree of improvement was modest (George et al., 1997). Herwig and colleagues (2003) reported similar findings with a 30% response rate to real rTMS, and none responded with sham treatment.

There are suggestions that longer duration of treatment may result in more significant improvement. Pridmore et al. (1999) were the first to extend the period of treatment to over two weeks. Patients with melancholic depression referred for ECT were treated with rTMS to the left DLPFC. This resulted in remission in 88% of cases in an open study. The data regarding the application of rTMS to treat major depression suggest that a longer period of stimulation could be required to evoke a clinical response (Gershon et al., 2003). An ongoing double-blind, sham-controlled, multicenter study on the efficacy of rTMS applied to the left DLPFC for six weeks will test whether longer periods of stimulation are more effective in a controlled setting.

It is still an open question as to whether the antidepressant effects of rTMS are region- or frequency-dependent. Klein et al. (1999b) randomized outpatients with depression to two weeks of active slow (1 Hz) rTMS or sham treatment over the right prefrontal cortex using a round, nonfocal coil. In the active group, 49% of patients responded compared to 25% in the sham group. This study suggested that right-sided stimulation might be effective. A much smaller double-blind study replicated these results with the active group, showing a better clinical response compared to the sham treatment (Kauffmann et al., 2004).

If lower frequencies are indeed as effective as higher frequencies, this would have significant safety implications, as lower frequencies carry less risk of seizure. When low and high frequency have been compared in the same study, there are suggestions that participants who receive rTMS at lower frequencies may actually fare better. Kimbrell et al. (1999) found a trend toward better improvement following two weeks of left prefrontal rTMS at 1 Hz compared to 20 Hz in a crossover design. There were suggestions that baseline metabolic activity in the DLPFC correlated with response. Similarly, Padberg et al. (1999) tested patients with nonpsychotic depression with sham treatment, slow rTMS or fast rTMS, all over the left DLPFC. After five days, 83% in the slow group and 50% in the fast group improved, with no change in the sham group. A parallel-design, blinded study suggested that slower (5 Hz) left prefrontal TMS may be as effective as faster (20 Hz) stimulation (George et al., 2000). Fitzgerald et al. (2003) demonstrated that both high-frequency left rTMS and low-frequency right rTMS have benefits in patients with medication-resistant major depression. They concluded that treatment for at least four weeks is necessary for clinically meaningful benefits to be achieved.

There has been great interest in determining whether rTMS could offer an alternative to ECT for severe or treatment-resistant depression, particularly because the adverse-effect profile of rTMS is relatively benign. Using a parallel-group, nonblinded design, Grunhaus and colleagues (2000) randomly assigned inpatients to treatment with fast left DLPFC rTMS or ECT. Among patients who were nonpsychotic, up to four weeks of daily rTMS was not different in efficacy to ECT, but ECT was superior among patients with psychotic depression. Patients treated with rTMS or ECT showed the same percentage of clinical stabilization at three and six months of follow-up (Dannon et al., 2002). Janicak et al. (2002) randomized patients with severe depression to be treated with rTMS or ECT. No significant difference in efficacy was found between the two treatments for improvement on the Hamilton Rating Scale for Depression (HAM-D; 55% improved with rTMS, and 64% improved with ECT).

All these studies had the limitation that the patients were not blinded to the form of treatment, and some have questioned whether the ECT comparison group represented optimal ECT practice. Nevertheless, it would be impossible to blind the patient to the treatment modality in this case (because sham ECT would not be considered ethically acceptable), and all studies have found the side-effect profile to favor rTMS.

Several meta-analyses have examined the antidepressant efficacy of rTMS (Holtzheimer et al., 2001; Martin et al., 2003, 2001) and concluded that there is evidence for statistical benefit of rTMS. However, the effect size could be described as moderate and in some cases of limited clinical significance. For example, Burt et al. (2002) found an average percent improvement with active TMS of 28.94% (SD=23.19) and with sham treatment of 6.63% (SD=25.56). Relatively few patients met standard criteria for response or remission.

It is also true, however, that the meta-analyses are heavily weighted towards the earlier studies that used what may now be considered to be adequate dosages and durations of rTMS.

Further work using controlled designs is needed to determine whether the antidepressant effects of rTMS are region-, frequency- or intensity-dependent, and to test the efficacy of more robust parameters in a sample large enough to provide adequate statistical power.

Such work is presently underway, with multicenter trials sponsored both by industry and the National Institute of Mental Health.


Electroconvulsive therapy is effective in depression as well as in mania, so it was hypothesized that rTMS might likewise have similar efficacy. It was also thought from imaging studies and post-stroke mood effects that the laterality of mania may be opposite to that of depression and involve more heavily the right prefrontal cortex.

In the first study of rTMS for acute mania, Belmaker and Grisaru (1999) tested that hypothesis by randomly assigning patients with mania to fast rTMS to the left or right DLPFC as an add-on to standard pharmacotherapy. After two weeks, the group treated with right DLPFC rTMS did better, consistent with the theory that the laterality of fast rTMS necessary for antimanic effects is opposite to that needed for antidepressant effects. However, they could not replicate the antimanic effect in a subsequent follow-up study of right active rTMS versus right sham rTMS, wherein right rTMS was no more effective than sham rTMS. It is possible that the previous results were due to a worsening effect of left rTMS on mania. Additionally, this patient group had much more psychosis than the previous study of rTMS in mania, and depression studies have reported that psychosis is a poor prognostic sign for rTMS response (Kaptsan et al., 2003). More recently, a study of a four-week course of rTMS showed a sustained reduction of manic symptoms in all patients (Michael and Erfurth, 2004). Due to the open, add-on design of the study, a clear causal relationship between rTMS treatment and reduction of manic symptoms could not be established.


The first studies on patients with schizophrenia employed TMS administered with a large round coil to the vertex, thereby stimulating broad regions of bilateral prefrontal and parietal cortices. In 1997, Geller and colleagues reported that 60% of medicated patients with chronic schizophrenia showed some transient improvement following a single session of rTMS in an open study. Using two weeks of 1-Hz rTMS with a smaller round coil positioned on the right prefrontal cortex, 70% of treated patients with schizophrenia were moderately or markedly improved, and psychosis ratings dropped significantly (Feinsod et al., 1998). However, when the same group followed up their findings with a sham-controlled trial, rTMS did not differ from sham (Klein et al., 1999a).

Hoffman et al. (1999) had more success with 1-Hz rTMS when the coil was positioned over the left temporoparietal cortex, a region that has shown selective activation during auditory hallucinations. This trial was based upon the hypothesis that low-frequency rTMS may dampen excitability in the region implicated in this specific symptom (Chen et al., 1997). In an initial crossover study, significant reductions in auditory hallucinations were noted with active rTMS compared with sham treatment (Hoffman et al., 1999). Two of three patients experienced a near-total cessation of auditory hallucinations for at least two weeks. Significant reductions in auditory hallucinations were replicated in a larger crossover trial by the same group (Hoffman et al., 2000).

Other groups have examined the effects of high-frequency rTMS applied to the prefrontal cortex on the theory that high-frequency rTMS might be useful in reversing the hypofrontality observed in schizophrenia. In an open study of patients who received 20-Hz rTMS to the midline prefrontal cortex for at least two weeks, a significant reduction in negative symptoms was observed, but other symptoms and tests of neuropsychological function were essentially unchanged (Cohen et al., 1999). A single session of 20-Hz rTMS was administered to the left DLPFC in a sham-controlled, crossover trial (Nahas et al., 1999). Improvement in negative symptoms was noted the day following treatment. In a more recent two-week, crossover-controlled study, another group reported that active rTMS significantly decreased psychotic symptoms (Rollnik et al., 2000). More controlled studies need to be done to determine whether high-frequency rTMS will be helpful for negative symptoms.

Panic Disorder

Limited studies, mostly case series, have been conducted on the therapeutic applications of rTMS in anxiety disorders. The majority of neuroimaging studies have shown elevated right-sided activity in the frontal and hippocampal-parahippocampal regions in fear paradigms and anxiety disorders. This has led to the hypothesis that low-frequency rTMS may be helpful in dampening that lateralized hyperexcitability, similar to the rationale behind using 1-Hz rTMS for the positive symptoms of schizophrenia.

Zwanzger et al. (2002) demonstrated a reduction of panic symptoms with a marked improvement of anxiety in an open case study of a patient treated for two weeks with slow rTMS on the right DLPFC. Anxiety symptoms decreased by 78%, and panic/agoraphobia symptoms decreased by 59%. Improvements lasted at one-month follow-up. Interestingly, there was a reduction in cholecystokinin tetrapeptide (CCK-4)-induced panic attacks, associated with blunting of the CCK-4-induced elevation of serum cortisol.

In another open case series, three patients with treatment-resistant panic disorder showed modest improvement with 10 rTMS sessions (1 Hz, 110% of motor threshold, 30 trains of 60-second duration) to the right DLPFC (Garcia-Toro et al., 2002). Alternating low-frequency rTMS to the right DLPFC with 20-Hz rTMS to the left DLPFC failed to produce further benefits. There has yet to be a sham-controlled trial of rTMS in the treatment of panic.


McCann et al. (1998) treated two patients with treatment-resistant posttraumatic stress disorder, both of whom showed elevated baseline cerebral metabolism on positron emission tomography (PET). Slow rTMS to the right DLPFC reduced posttraumatic symptoms and reversed cerebral hypermetabolism, most markedly in the right prefrontal cortex.

In line with symptom provocation studies that have demonstrated significantly greater activity in patients with PTSD in brain regions associated with motor preparedness in response to threat, Grisaru et al. (1998) applied 0.3-Hz rTMS bilaterally to the motor cortex of patients with PTSD. Posttraumatic stress symptom scores improved transiently, but this may underestimate the value of such an approach because the stimulation parameters were overly conservative (only 30 pulses per day).

Rosenberg et al. (2002) hypothesized that left frontal rTMS (either 1 Hz or 5 Hz, 90% of motor threshold, total 6000 stimuli) could mimic the beneficial effect of antidepressant medications in patients with combat PTSD and comorbid major depression. They found that 75% of patients had a clinically significant antidepressant response, but just minimal improvements in PTSD symptomatology. At two-month follow-up, the antidepressant effects were maintained in half the patients.

Cohen et al. (2004), in a double-blind, sham-controlled trial, found beneficial effects of rTMS at 10 Hz, but not at 1 Hz or with sham rTMS, to the right DLPFC in patients with PTSD core symptoms (re-experiencing, avoidance) and other anxiety symptoms. The frequency specificity of these effects, demonstrated in the context of a well-controlled study, offered strong support that the use of rTMS in this disorder is worth exploring further.


Neurophysiological data converge in indicating that cognitive impairment and motor "intrusive" and repetitive behaviors in obsessive-compulsive disorder may be a consequence of a reduction of cortico-cortical inhibitory phenomena and a higher than normal level of cortical excitability. Greenberg et al. (2000, 1998) used the technique of paired-pulse TMS to test whether deficient intracortical inhibition exists in OCD. They found that patients with OCD, like those with Tourette's disorder, had markedly decreased intracortical inhibition. Those with tic-related OCD showed the most profound deficit in intracortical inhibition. Additionally, patients with OCD had lower resting and active motor thresholds than did normal volunteers.

Imaging studies of OCD implicate hyperactivity in a circuit involving orbitofrontal cortex and basal ganglia. To test whether modulating activity in this network could influence OCD symptoms, Greenberg et al. (1997) administered rTMS to the right lateral prefrontal, left lateral prefrontal and a midoccipital (control) site on separate days in a blinded trial. Patients' compulsive urges decreased significantly for eight hours after right lateral prefrontal rTMS. A short-lasting, modest and nonsignificant reduction in compulsive urges occurred after left lateral prefrontal rTMS.

Two other studies have examined possible therapeutic effects of rTMS in OCD. A double-blind study using right prefrontal 1-Hz rTMS and a less focal coil failed to find statistically significant effects greater than sham treatment (Alonso et al., 2001). In contrast, an open study in a group of patients with OCD refractory to standard treatments who were randomly assigned to right or left prefrontal fast rTMS found that clinically significant and sustained improvement was observed in a quarter of the patients (Sachdev et al., 2001). More work will be needed to clarify whether rTMS will be helpful in OCD, but the availability of a defined circuitry should guide the design of such trials.


Routine clinical use of rTMS in psychiatric disorders is far from certain at the present time, but that may change as the results of larger well-controlled trials become available. None of the key effects has been rigorously replicated, and most of the positive findings are based on small samples in short-duration trials. Depression is the condition with the most consistent evidence, but there are discrepancies among the initial studies in the magnitude and nature of the effects. In addition to the usual concerns about sample comparability and the reliability of assessment, the therapeutic application of rTMS has particular methodological issues involving sham application and the parameters used.

In any case, the initial studies suggest that rTMS can exert a variety of both short- and long-term behavioral effects. On the optimistic side, they raise the possibility that focal modulation of cortical excitability can have therapeutic properties in psychiatric disorders and that TMS may prove informative about the anatomy and physiology of the neural systems involved in achieving therapeutic effects. At the clinical level, because its adverse-effect profile is so benign, rTMS may ultimately offer a less-invasive alternative to already established somatic interventions for severe or treatment-resistant illnesses.


Dr. Lisanby has received research grants from The Magstim Company Ltd., Neuronetics, National Institute of Mental Health, National Alliance for Research on Schizophrenia and Depression, the Stanley Foundation, and the American Federation for Aging Research.

Dr. Mantovani is a postdoctoral research fellow in the department of biological psychiatry at the New York State Psychiatric Institute and the department of neuroscience at Siena University.

Dr. Lisanby directs the Magnetic Brain Stimulation Laboratory and the Brain-Behavior Clinic of the New York State Psychiatric Institute and the Columbia Depression Center.




Alonso P, Pujol J, Cardoner N et al. (2001), Right prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Am J Psychiatry 158(7):1143-1145.


Belmaker RH, Grisaru N (1999), Antibipolar potential for transcranial magnetic stimulation. Bipolar Disord 1(2):71-72.


Belmaker B, Fitzgerald P, George MS et al. (2003), Managing the risks of repetitive transcranial stimulation. CNS Spectr 8(7):489.


Burt T, Lisanby SH, Sackeim HA (2002), Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. Int J Neuropsychopharmacol 5(1):73-103.


Chen R, Classen J, Gerloff C et al. (1997), Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation. Neurology 48(5):1398-1403.


Cohen E, Bernardo M, Masana J et al. (1999), Repetitive transcranial magnetic stimulation in the treatment of chronic negative schizophrenia: a pilot study. J Neurol Neurosurg Psychiatry 67:129-130.


Cohen H, Kaplan Z, Kotler M et al. (2004), Repetitive transcranial magnetic stimulation of the right dorsolateral prefrontal cortex in posttraumatic stress disorder: a double-blind, placebo-controlled study. Am J Psychiatry 161(3):515-524.


Dannon PN, Dolberg OT, Schreiber S, Grunhaus L (2002), Three and six-month outcome following courses of either ECT or rTMS in a population of severely depressed individuals--preliminary report. Biol Psychiatry 51(8):687-690.


Feinsod M, Kreinin B, Chistyakov A, Klein E (1998), Preliminary evidence for a beneficial effect of low-frequency, repetitive transcranial magnetic stimulation in patients with major depression and schizophrenia. Depress Anxiety 7(2):65-68.


Fitzgerald PB, Brown TL, Marston NA et al. (2003), Transcranial magnetic stimulation in the treatment of depression: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 60(10):1002-1008.


Garcia-Toro M, Salva Coll J, Crespi Font M et al. (2002), [Panic disorder and transcranial magnetic stimulation.] Actas Esp Psiquiatr 30(4):221-224.


Geller V, Grisaru N, Abarbanel JM et al. (1997), Slow magnetic stimulation of prefrontal cortex in depression and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 21(1):105-110.


George MS, Wassermann EM, Kimbrell TA et al. (1997), Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial. Am J Psychiatry 154(12):1752-1756.


George MS, Nahas Z, Molloy M et al. (2000), A controlled trial of daily left prefrontal cortex TMS for treating depression. Biol Psychiatry 48(10):962-970.


Gershon AA, Dannon PN, Grunhaus L (2003), Transcranial magnetic stimulation in the treatment of depression. Am J Psychiatry 160(5):835-845.


Greenberg BD, George MS, Martin JD et al. (1997), Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a preliminary study. Am J Psychiatry 154(6):867-869.


Greenberg BD, Ziemann U, Cora-Locatelli G et al. (2000), Altered cortical excitability in obsessive-compulsive disorder. Neurology 54(1):142-147.


Greenberg BD, Ziemann U, Harmon A et al. (1998), Decreased neuronal inhibition in cerebral cortex in obsessive-compulsive disorder on transcranial magnetic stimulation. Lancet 352(9131):881-882.


Grisaru N, Amir M, Cohen H, Kaplan Z (1998), Effect of transcranial magnetic stimulation in posttraumatic stress disorder: a preliminary study. Biol Psychiatry 44(1):52-55.


Grunhaus L, Dannon PN, Schreiber S et al. (2000), Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder: an open study. Biol Psychiatry 47(4):314-324.


Herwig U, Lampe Y, Juengling FD et al. (2003), Add-on rTMS for treatment of depression: a pilot study using stereotaxic coil-navigation according to PET data. J Psychiatr Res 37(4):267-275.


Hoffman RE, Boutros NN, Berman RM et al. (1999), Transcranial magnetic stimulation of left temporoparietal cortex in three patients reporting hallucinated "voices." Biol Psychiatry 46(1):130-132.


Hoffman RE, Boutros NN, Hu S et al. (2000), Transcranial magnetic stimulation and auditory hallucinations in schizophrenia. Lancet 355(9209):1073-1075.


Holtzheimer PE 3rd, Russo J, Avery DH (2001), A meta-analysis of repetitive transcranial magnetic stimulation in the treatment of depression. Psychopharmacol Bull 35(4):149-169.


Janicak PG, Dowd SM, Martis B et al. (2002), Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: preliminary results of a randomized trial. Biol Psychiatry 51(8):659-667.


Kaptsan A, Yaroslavsky Y, Applebaum J et al. (2003), Right prefrontal TMS versus sham treatment of mania: a controlled study. Bipolar Disord 5(1):36-39.


Kauffmann CD, Cheema MA, Miller BE (2004), Slow right prefrontal transcranial magnetic stimulation as a treatment for medication-resistant depression: a double-blind, placebo-controlled study. Depress Anxiety 19(1):59-62.


Kimbrell TA, Little JT, Dunn RT et al. (1999), Frequency dependence of antidepressant response to left prefrontal repetitive transcranial magnetic stimulation (rTMS) as a function of baseline cerebral glucose metabolism. Biol Psychiatry 46(12):1603-1613.


Klein E, Kolsky Y, Puyerovsky M et al. (1999a), Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double-blind sham-controlled pilot study. Biol Psychiatry 46(10):1451-1454.


Klein E, Kreinin I, Chistyakov A et al. (1999b), Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression: a double-blind controlled study. Arch Gen Psychiatry 56(4):315-320.


Martin JL, Barbanoj MJ, Schlaepfer TE et al. (2001), Transcranial magnetic stimulation for treating depression. Cochrane Database Syst Rev (2):CD003493.


Martin JL, Barbanoj MJ, Schlaepfer TE et al. (2003), Repetitive transcranial magnetic stimulation for the treatment of depression. Systematic review and meta-analysis. Br J Psychiatry 182:480-491.


McCann UD, Kimbrell TA, Morgan CM et al. (1998), Repetitive transcranial magnetic stimulation for posttraumatic stress disorder. Arch Gen Psychiatry 55(3):276-279.


Michael N, Erfurth A (2004), Treatment of bipolar mania with right prefrontal rapid transcranial magnetic stimulation. J Affect Disord 78(3):253-257.


Nahas Z, McConnell K, Collins S et al. (1999), Could left prefrontal rTMS modify negative symptoms and attention in schizophrenia? Biol Psychiatry 45:37S.


Padberg F, Zwanzger P, Thoma H et al. (1999), Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: comparative study of fast, slow and sham rTMS. Psychiatry Res 88(3):163-171.


Pascual-Leone A, Rubio B, Pallardo F, Catala MD (1996), Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet 348(9022):233-237.


Pridmore S, Rybak M, Turnier-Shea Y et al. (1999), A naturalistic study of response in melancholia to transcranial magnetic stimulation (TMS). German Journal of Psychiatry 2:13-21.


Rollnik JD, Huber TJ, Mogk H et al. (2000), High frequency repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex in schizophrenic patients. Neuroreport 11(18):4013-4015.


Rosenberg PB, Mehndiratta RB, Mehndiratta YP et al. (2002), Repetitive transcranial magnetic stimulation treatment of comorbid posttraumatic stress disorder and major depression. J Neuropsychiatry Clin Neurosci 14(3):270-276.


Sachdev PS, McBride R, Loo CK et al. (2001), Right versus left prefrontal transcranial magnetic stimulation for obsessive-compulsive disorder: a preliminary investigation. J Clin Psychiatry 62(12):981-984.


Triggs WJ, McCoy KJ, Greer R et al. (1999), Effects of left frontal transcranial magnetic stimulation on depressed mood, cognition, and corticomotor threshold. Biol Psychiatry 45(11):1440-1446.


Wassermann EM (1998), Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. Electroencephalogr Clin Neurophysiol 108(1):1-16.


Zwanzger P, Minov C, Ella R et al. (2002), Transcranial magnetic stimulation for panic. Am J Psychiatry 159(2):315-316.

Related Videos
Erin Crown, PA-C, CAQ-Psychiatry, and John M. Kane, MD, experts on schizophrenia
brain depression
nicotine use
brain schizophrenia
eating disorder brain
© 2024 MJH Life Sciences

All rights reserved.